Bone tissue engineering and regenerative medicine: targeting pathological fractures.

Area of Science:

• Biomaterials Science
• Orthopedic Surgery
• Regenerative Medicine

Background:

• Bone diseases increase fracture and nonunion risks due to tissue degeneration.
• Current fracture management strategies are inadequate for diseased bone, leading to complications like implant failure and nonunion.
• Fragility fractures require specialized treatments that consider the pathological bone environment.

Purpose of the Study:

• To highlight the limitations of current fracture management in diseased bone.
• To propose the development of bioactive bone substitutes tailored for pathological bone environments.
• To emphasize the need for in vitro models to predict the clinical effectiveness of engineered bone substitutes.

Main Methods:

• Review of current fracture management strategies (pharmaceutical, surgical, tissue regeneration).
• Discussion of the challenges posed by pathological bone environments in fragility fractures.
• Proposal for the development and testing of bioactive bone substitutes in simulated physiological in vitro bone environments.

Main Results:

• Current strategies often fail to address the complexities of fragility fractures.
• Bioactive bone substitutes designed for pathological environments are needed.
• Predicting clinical outcomes requires simulating the in vitro bone environment.

Conclusions:

• Effective management of fragility fractures necessitates advanced strategies beyond current approaches.
• Bioactive bone substitutes and predictive in vitro testing are essential for improving bone healing in diseased bone.
• In vitro test systems can reduce implant failures and nonunions in fragility fractures.